中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(3): 616-620

Value of Modified Response Evaluation Criteria in Solid Tumors response in predicting the prognosis of patients with unresectable hepatocellular carcinoma patients after transarterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2021.03.022
  • 1.

    Air Force Medical University, Xi'an 710032, China

  • 2a.

    Department of Liver Disease and Digestive Interventional Radiology, The First Affiliated Hospital of Air Force Medical University, Xi'an 710032, China

  • 2b.

    Department of Hepatobiliary, Pancreatic and Splenic Surgery, The First Affiliated Hospital of Air Force Medical University, Xi'an 710032, China

  • Received Date: 2020-11-05
  • Accepted Date: 2020-12-24
  • Published Date: 2021-03-20
    Abstract
  •   Objective  To investigate the association of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) response with the prognosis of patients with unresectable hepatocellular carcinoma (HCC) after transarterial embolization (TACE).  Methods  A retrospective analysis was performed for the clinical data of 190 patients with unresectable HCC who were consecutively admitted to Department of Liver Disease and Digestive Interventional Radiology, The First Affiliated Hospital of Air Force Medical University, and treated with TACE from January 2010 to December 2014. The mRECIST criteria were used to evaluate imaging response after TACE; the patients with complete response (CR) or partial response (PR) were enrolled as response group (n=89), and those with progressive disease (PD) or stable disease (SD) were enrolled as non-response group (n=101). The Kaplan-Meier method was used to calculate median survival time, and the log-rank test was used for comparison between groups; the Cox regression model was used to identify the influencing factors for prognosis.  Results  According to the mRECIST criteria, 39 patients (20.5%) achieved CR, 50 (26.3%) achieved PR, 67 (35.3%) had SD, and 34 (17.9%) had PD. The objective response rate based on mRECIST was 46.8% for the whole population. The response group had a significantly longer survival time than the non-response group, and the median survival time was 29.9 (95% confidence interval [CI]: 25.0-34.8) months for the response group and 7.5 (95% CI: 5.7-9.3) months for the non-response group (P < 0.001). The multivariate analysis showed that mRECIST response (hazard ratio [HR]=2.02, P < 0.001), hepatitis B (HR=4.03, P < 0.001), and portal invasion (HR=2.12, P=0.008) were independent risk factors for survival.  Conclusion  The mRECIST response has a certain value in predicting the prognosis of patients with unresectable HCC after TACE.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    MARRERO JA, KULIK LM, SIRLIN C, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-50. DOI: 10.1002/hep.29913
    [2]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019
    [3]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
    [4]
    SIEGHART W, HUCKE F, PECK-RADOSAVLJEVIC M. Transarterial chemoembolization: Modalities, indication, and patient selection[J]. J Hepatol, 2015, 62(5): 1187-1195. DOI: 10.1016/j.jhep.2015.02.010
    [5]
    LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132
    [6]
    GILLMORE R, STUART S, KIRKWOOD A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization[J]. J Hepatol, 2011, 55(6): 1309-1316. DOI: 10.1016/j.jhep.2011.03.007
    [7]
    JUNG ES, KIM JH, YOON EL, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. J Hepatol, 2013, 58(6): 1181-1187. DOI: 10.1016/j.jhep.2013.01.039
    [8]
    KIM BK, KIM KA, PARK JY, et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation[J]. Eur J Cancer, 2013, 49(4): 826-834. DOI: 10.1016/j.ejca.2012.08.022
    [9]
    PRAJAPATI HJ, SPIVEY JR, HANISH SI, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)[J]. Ann Oncol, 2013, 24(4): 965-973. DOI: 10.1093/annonc/mds605
    [10]
    KIM CJ, KIM HJ, PARK JH, et al. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma[J]. Liver Int, 2014, 34(2): 305-312. DOI: 10.1111/liv.12270
    [11]
    KIM BK, KIM SU, KIM KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma[J]. J Hepatol, 2015, 62(6): 1304-1310. DOI: 10.1016/j.jhep.2015.01.022
    [12]
    VINCENZI B, MAIO MD, SILLETTA M, et al. Prognostic relevance of objective response according to EASL Criteria and mRECIST Criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based Meta-analysis[J]. Plos One, 2015, 10(7): 1-12. DOI: 10.1371/journal.pone.0133488
    [13]
    TACHER V, LIN M, DURAN R, et al. Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach[J]. Radiology, 2016, 278(1): 275-284. DOI: 10.1148/radiol.2015142951
    [14]
    GEORGIADES C, GESCHWIND JF, HARRISON N, et al. Lack of response after initial chemoembolization for hepatocellular carcinoma: Does it predict failure of subsequent treatment?[J]. Radiology, 2012, 265(1): 115-123. DOI: 10.1148/radiol.12112264
    [15]
    LIU L, WANG W, CHEN H, et al. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(6): 1623-1631. DOI: 10.1158/1078-0432.CCR-13-1716
    [16]
    SHIM JH, LEE HC, KIM SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models[J]. Radiology, 2012, 262(2): 708-718. DOI: 10.1148/radiol.11110282
    [17]
    JUNG YK, JUNG CH, SEO YS, et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A[J]. J Gastroenterol Hepatol, 2016, 31(2): 467-474. DOI: 10.1111/jgh.13152
    [18]
    ZHAO Y, WANG WJ, GUAN S, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: A large-scale multicenter study of 222 patients[J]. Ann Oncol, 2013, 24(7): 1786-1792. DOI: 10.1093/annonc/mdt072
    [19]
    WANG YY, ZHONG JH, XU HF, et al. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour > 7 cm and multiple tumours beyond up-to-seven criteria[J]. Aliment Pharmacol Ther, 2019, 49(2): 202-210. DOI: 10.1111/apt.15074
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1045) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return